Seattle Genetics- The Prominent Pharmaceutical
MicroRNA is based in therapeutics mainly focusing on cancer research. The Company was founded in 2007; it is located in Austin, Texas. Seattle Genetics has received significant funding from private stockholders and the State of Texas, in cooperation with the State’s Emerging Technology Fund. Its initial commercial product was ADCETRIS. It was accepted in August 2011Seattle Genetics has an extensive pipeline of additional product candidates. It has also entered into numerous strategic partnerships with leading pharmaceutical and biotechnology companies in oncology. The company has had capital-raising events, thus securing about 675 million dollars through private and public financings.
The organization has a foundational scholarly property portfolio about the use therapeutic usage of miRNAs established by their scientists and also in-licensed from other organizations. Its portfolio contains over three hundred miRNAs with submissions in oncology and other different diseases.
What microRNAs are about
MiRNAs are roughly 20 to 25 nucleotides long, and they affect gene expression by interfering with messenger RNAs. Dissimilar to siRNAs, miRNAs are encrypted in the genome and are useful as natural controllers of universal gene expression. Over 1,400 miRNAs comprise approximately two percent of the mammalian genes. Each miRNA seems to regulate the expression of thousands of different genes, and they can function as master switches proficiently coordinating and regulating multiple cellular processes and pathways. MiRNAs are also responsible for controlling proper embryonic development, inflammation, immunity and cellular growth and proliferation.
Clay B. Siegall Appointment as CEO
Mirna Therapeutics Inc. appointed Clay Siegall, who holds Ph.D., to its Board of Directors in January 2013 – Mirna Therapeutics, which is a biotechnology company dedicated to the commercialization and development of microRNA. Clay B.Siegall was appointed the CEO and Chairperson of Board of Directors of the Seattle Genetics, acting as an outside director to the Board of Directors. Dr Siegall has a rich background in pharmaceutical industry achievements and experience in building a fruitful oncology company. Dr Clay Siegall was one of the founders of Seattle Genetics, under his management, the company has constructed various pipelines of antibody-based treatments to address unsolved cancer patients medical needs.